Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study from Italy Emphasizing Head and Neck Areas - Summary - MDSpire

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study from Italy Emphasizing Head and Neck Areas

  • By

  • Luigi Gargiulo

  • Luciano Ibba

  • Matteo Bianco

  • Sara Di Giulio

  • Mario Valenti

  • Gianluca Avallone

  • Martina Zussino

  • Paolo Calzari

  • Angelo Valerio Marzano

  • Antonio Costanzo

  • Silvia Mariel Ferrucci

  • Alessandra Narcisi

  • March 28, 2026

  • 0 min

Share

Objective:

To evaluate the long-term effectiveness and safety of lebrikizumab in treating moderate-to-severe atopic dermatitis, particularly in head and neck areas, in a real-world setting, emphasizing its clinical implications.

Key Findings:
  • Lebrikizumab demonstrated sustained effectiveness over 52 weeks, with EASI scores improving significantly.
  • Clinical responses were maintained with Q4W dosing, regardless of head and neck involvement, with specific numerical data.
  • Patients reported significant improvements in EASI scores, with detailed percentages.
Interpretation:

Lebrikizumab is effective and safe for long-term treatment of moderate-to-severe atopic dermatitis, including in challenging head and neck areas, supporting its use in clinical practice.

Limitations:
  • Retrospective design may limit data completeness and generalizability, particularly due to the small sample size for head and neck involvement analysis at week 52.
Conclusion:

Lebrikizumab is a promising treatment option for patients with moderate-to-severe atopic dermatitis, showing sustained efficacy and safety in a real-world setting, highlighting its potential role in clinical practice.

Original Source(s)

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study from Italy Emphasizing Head and Neck Areas

  • by Luigi Gargiulo, Luciano Ibba, Matteo Bianco, Sara Di Giulio, Mario Valenti, Gianluca Avallone, Martina Zussino, Paolo Calzari, Angelo Valerio Marzano, Antonio Costanzo, Silvia Mariel Ferrucci, Alessandra Narcisi

  • March 28, 2026

Related Content

Evaluation of Baricitinib Administration for Atopic Dermatitis Patients in Spain: Insights from the DAMA-S Retrospective Chart Analysis

AI Falls Short on Differential Dx

New PrIME-LLM benchmark shows strong diagnostic accuracy but persistent gaps in clinical reasoning across 21 large language models

Who Decides When a Doctor Steps Back?

Cognitive decline, credentialing, and why “I’ll know” often isn’t enough.